BCMA, Elranatamab-bcmm, multiple myeloma
Elranatamab-bcmm receives accelerated approval by FDA for multiple myeloma
Nov 2023: Elranatamab-bcmm (Elrexfio, Pfizer, Inc.) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager that was given accelerated approval by the Food and Drug Administration for adults with relapsed or ..
Janssen Biotech, MonumenTAL-1, multiple myeloma, Talquetamab-tgvs, Talvey
Talquetamab-tgvs has received accelerated approval for relapsed or refractory multiple myeloma
August 2023: Talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) has been given accelerated approval by the Food and Drug Administration for the treatment of adults with relapsed or refractory multiple myeloma who have undergone at ..
bispecific T-cell engager, BiTE, BiTE therapy, multiple myeloma
Development and future potential of the BiTE (bispecific T-cell engager) platform
Immuno-oncology is a way to treat cancer by using the body's immune system. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that binds a patient's own T cells to cancer cells. Because BiTE techno..
Arcellx, CAR T Therapy, CART DDBCMA, chimeric antigen receptor, Kite Pharma, multiple myeloma
KITE AND ARCELLX CLOSE AGREEMENT TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA
SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic..
CAR - T Cell therapy, China, IASO Biotherapeutics, multiple myeloma
CAR T-cell treatment from IASO Biotherapeutics receives new FDA approval
Feb 2023: IASO Biotherapeutics' investigational CAR T-cell therapy for relapsed or refractory multiple myeloma (RRMM), CT103A, has received fast track and regenerative medicine advanced therapy designations from the U.S. Food and..
Amgen, carfilzomib, Darzalex Faspro, dexamethasone, Janssen Biotech, Kyprolis, multiple myeloma
Darzalex faspro, kyprolis, and dexamethasone is approved by FDA for multiple myeloma
March 2022: Daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen, Inc.) plus dexamethasone have been approved by the Food and Drug Administration for adult patients with relap..
CD-38, FDA, HORIZON, immunomodulatory agent, melphalan flufenamide, multiple myeloma, NCT02963493, Oncopeptides AB, Pepaxto
Melphalan flufenamide receives approval from the FDA for relapsed or refractory multiple myeloma
August 2021: Melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with dexamethasone has been granted accelerated approval by the Food and Drug Administration for adult patients with relapsed or refractory multiple myel..